Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Joint CMA response labels remedies 'disproportionate'
One remedy has been described as 'anti-competitive' in the response.
The response is signed by leading organisations, including BVA and SPVS.

A joint response to the Competition and Markets Authority (CMA) provisional decision report has criticised some measures as 'disproportionate' and detrimental to many in the veterinary industry.

Published on 14 November, the document raises significant concerns with the CMA's approach to medicine market remedies, particularly in regards to online pharmacies. It is signed by BVA, BSAVA, SPVS, VMG and BVNA.

The response warns that requirements to make pet owners aware that medicines can be bought cheaply online could threaten the veterinary sector. This remedy is being criticised as 'anti-competitive', since it would limit supply routes to 'a small number of online pharmacies'.

It has suggested this could be particularly detrimental to veterinary businesses which do not operate online pharmacies. The response warns that a focus on online pharmacies risks ignoring other appropriate and available routes for medicine supplies.

Data from the BVA's Voice of the Veterinary Profession survey found that 64 per cent of veterinary surgeons considered that directing clients to online pharmacies would negatively impact the financial sustainability of their practice.

The organisations have also voiced disapproval with a proposed cap on prescription fees, which would see practices charge a fixed rate of £16 per consult. The Voice of the Profession survey revealed that 65 per cent of veterinary surgeons considered the prescription price cap damaging to practice viability.

The response says that 'further refinement' is needed to ensure that the access price for veterinary care is not negatively impacted by this remedy. It suggests that changing the veterinary market in this way risks increasing the costs of common and high-volume access point professional services.

However, the organisations have remained largely supportive of many of the CMA's remedies.

Despite its criticisms, the response describes the provisional decision as 'more measured and proportionate' than those proposed in the CMA's working paper earlier this year. It notes that remedies previously flagged as burdens to veterinary practices had been modified or dropped entirely.

The response expresses support for requirements for practices to publish ownership information, standardised complaints processes, and veterinary legislative reform.

Rob Williams, BVA president, said: “The measures outlined in the CMA’s provisional decision report are much more measured and proportionate compared to earlier proposals and that clearly shows they have listened to our concerns.

“As vets, we welcome the measures that increase transparency and help us to better support our clients. However, it’s vital that the CMA gets the detail right or it risks unintended negative consequences.”

The full joint response can be read here.

Image © KimberlyThomas/Shutterstock.com

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.